Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Daniel H Kwon, Eric K Nakakura, Emily K Bergsland & Sun-Chuan Dai. (2017) Gastric neuroendocrine tumors: management and challenges. Gastrointestinal Cancer: Targets and Therapy 7, pages 31-37.
Read now
Read now
Andrea Giustina, Gherardo Mazziotti, Filippo Maffezzoni, Vito Amoroso & Alfredo Berruti. (2014) Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opinion on Investigational Drugs 23:12, pages 1619-1635.
Read now
Read now
Constantin S. Jianu, Reidar Fossmark, Unni Syversen, Øyvind Hauso, Vidar Fykse & Helge L. Waldum. (2011) Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scandinavian Journal of Gastroenterology 46:4, pages 456-463.
Read now
Read now
Eva Tiensuu Janson, Halfdan Sørbye, Staffan Welin, Birgitte Federspiel, Henning Grønbæk, Per Hellman, Øystein Mathisen, Jann Mortensen, Anders Sundin, Espen Thiis-Evensen, Matti J. Välimäki, Kjell Öberg & Ulrich Knigge. (2010) Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncologica 49:6, pages 740-756.
Read now
Read now
Karin Bakkelund, Reidar Fossmark, Ivar S. Nordrum & Helge L. Waldum. (2009) Effect of antrectomy in hypergastrinaemic female Japanese cotton rats. Scandinavian Journal of Gastroenterology 44:1, pages 32-39.
Read now
Read now
Jørgen Valeur, Anne Marita Milde, Karen B. Helle & Arnold Berstad. (2008) Low serum chromogranin A in patients with self-reported food hypersensitivity. Scandinavian Journal of Gastroenterology 43:11, pages 1403-1404.
Read now
Read now
Vidar Fykse, Arne Kristian Sandvik & Helge Lyder Waldum. (2005) One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scandinavian Journal of Gastroenterology 40:11, pages 1269-1274.
Read now
Read now
Articles from other publishers (53)
Luigi Asmundo, Valentina Ambrosini, Mark A. Anderson, Stefano Fanti, William R. Bradley, Davide Campana, Amirkasra Mojtahed, Ryan Chung, Shaunagh Mcdermott, Subba Digumarthy, Stephan Ursprung, Konstantin Nikolau, Florian J. Fintelmann, Michael Blake, Carlos Fernandez-del Castillo, Motaz Qadan, Ankur Pandey, Jeffrey W. ClarkOnofrio A. Catalano. (2024) Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach. Journal of Computer Assisted Tomography.
Crossref
Crossref
Fernando Sebastian-Valles, Blanca Bernaldo Madrid, Carolina Sager, Elena Carrillo López, Sara Mera Carreiro, Laura Ávila Antón, Noelia Sánchez-Maroto García, Miguel Antonio Sampedro-Nuñez, Jose Ángel Díaz Pérez & Mónica Marazuela. (2023) Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors. Biomedicines 11:3, pages 872.
Crossref
Crossref
Helge Waldum & Patricia Mjønes. (2020) Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells. Cancers 12:11, pages 3477.
Crossref
Crossref
Roberta Elisa Rossi, Pietro Invernizzi, Vincenzo Mazzaferro & Sara Massironi. (2020) Response and relapse rates after treatment with long‐acting somatostatin analogs in multifocal or recurrent type‐1 gastric carcinoids: A systematic review and meta‐analysis. United European Gastroenterology Journal 8:2, pages 140-147.
Crossref
Crossref
Katie A. Lloyd, Bryony N. Parsons, Michael D. Burkitt, Andrew R. Moore, Stamatia Papoutsopoulou, Malcolm Boyce, Carrie A. Duckworth, Klaire Exarchou, Nathan Howes, Lucille Rainbow, Yongxiang Fang, Claus Oxvig, Steven Dodd, Andrea Varro, Neil Hall & D. Mark Pritchard. (2020) Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors. Cellular and Molecular Gastroenterology and Hepatology 10:1, pages 113-132.
Crossref
Crossref
Helge L. Waldum, Øystein F. Sørdal & Patricia G. Mjønes. (2019) The Enterochromaffin-like [ECL] Cell—Central in Gastric Physiology and Pathology. International Journal of Molecular Sciences 20:10, pages 2444.
Crossref
Crossref
Craig R. Gluckman & David C. Metz. (2019) Gastric Neuroendocrine Tumors (Carcinoids). Current Gastroenterology Reports 21:4.
Crossref
Crossref
Massimo Carlini, Daniela Apa, Domenico Spoletini, Michele Grieco, Marialuisa Appetecchia, Francesca Rota, Salvatore Palazzo & Salvatore Turano. 2018. Abdominal Neuroendocrine Tumors. Abdominal Neuroendocrine Tumors
139
152
.
Davide Campana, Nico Pagano, Nicole Brighi, Dario Fabbri, Maria Rinzivillo, Gianfranco Delle Fave, Guido Biasco & Francesco Panzuto. 2018. Neuroendocrine Tumors in Real Life. Neuroendocrine Tumors in Real Life
219
234
.
Malcolm Boyce, Andrew R. Moore, Liv Sagatun, Bryony N. Parsons, Andrea Varro, Fiona Campbell, Reidar Fossmark, Helge L. Waldum & D. Mark Pritchard. (2016) Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. British Journal of Clinical Pharmacology 83:3, pages 466-475.
Crossref
Crossref
Helge L. Waldum, Liv Sagatun & Patricia Mjønes. (2017) Gastrin and Gastric Cancer. Frontiers in Endocrinology 8.
Crossref
Crossref
Davide Campana, Davide Ravizza, Piero Ferolla, Antongiulio Faggiano, Franco Grimaldi, Manuela Albertelli, Debora Berretti, Danilo Castellani, Giulia Cacciari, Nicola Fazio, Annamaria Colao, Diego Ferone & Paola Tomassetti. (2015) Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 51:1, pages 131-139.
Crossref
Crossref
Sara Massironi, Alessandra Zilli, Ilaria Fanetti, Clorinda Ciafardini, Dario Conte & Maddalena Peracchi. (2015) Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. Digestive and Liver Disease 47:11, pages 978-983.
Crossref
Crossref
Sara Massironi, Alessandra Zilli & Dario Conte. (2015) Somatostatin analogs for gastric carcinoids: For many, but not all. World Journal of Gastroenterology 21:22, pages 6785-6793.
Crossref
Crossref
Göran Åkerström, Peter Stålberg, Olov Norlén & Per Hellman. 2015. Neuroendocrine Tumours. Neuroendocrine Tumours
437
474
.
Oldrich Louthan. (2014) Neuroendocrine neoplasms of the stomach. Biomedical Papers 158:3, pages 455-460.
Crossref
Crossref
H. Dralle & I. Satiroglu. (2014) Endoskopische Resektion von Typ-1-MagenkarzinoidenEndoscopic resection of type 1 gastric neuroendocrine tumors. Der Chirurg 85:4, pages 347-347.
Crossref
Crossref
Ahmet Uygun, Abdurrahman Kadayifci, Zulfikar Polat, Kemalettin Yilmaz, Armagan Gunal, Hakan Demir & Sait Bagci. (2013) Long‐term results of endoscopic resection for type I gastric neuroendocrine tumors. Journal of Surgical Oncology 109:2, pages 71-74.
Crossref
Crossref
Andrew R. Moore, Malcolm Boyce, Islay A. Steele, Fiona Campbell, Andrea Varro & D. Mark Pritchard. (2013) Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis. PLoS ONE 8:10, pages e76462.
Crossref
Crossref
Sapna Rustagi, Jonathan Yao, Richard R.P. Warner & Celia M. Divino. (2013) Laparoscopic Antrectomy for Retained Antrum in Type 1 Gastric Carcinoid. Pancreas 42:6, pages 1040-1042.
Crossref
Crossref
Mark Kidd, Bjorn Gustafsson & Irvin M. Modlin. (2013) Gastric Carcinoids (Neuroendocrine Neoplasms). Gastroenterology Clinics of North America 42:2, pages 381-397.
Crossref
Crossref
Senthil V. Murugesan, Islay A. Steele, Rod Dimaline, Graeme J. Poston, Milind Shrotri, Fiona Campbell, Andrea Varro & D. Mark Pritchard. (2013) Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours. European Journal of Gastroenterology & Hepatology 25:4, pages 474-481.
Crossref
Crossref
Dimitrios Thomas, Apostolos V Tsolakis, Simona Grozinsky-Glasberg, Merav Fraenkel, Krystallenia Alexandraki, Stavros Sougioultzis, David J Gross & Gregory Kaltsas. (2013) Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. European Journal of Endocrinology 168:2, pages 185-193.
Crossref
Crossref
Christos Toumpanakis & Martyn E. Caplin. (2013) Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors. Seminars in Oncology 40:1, pages 56-68.
Crossref
Crossref
Moo In Park. (2013) Endoscopic Treatment for Early Foregut Neuroendocrine Tumors. Clinical Endoscopy 46:5, pages 450.
Crossref
Crossref
R. Fossmark, Ø. Sørdal, C. S. Jianu, G. Qvigstad, I. S. Nordrum, M. Boyce & H. L. Waldum. (2012) Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Alimentary Pharmacology & Therapeutics 36:11-12, pages 1067-1075.
Crossref
Crossref
Mark Kidd & Bjorn I. Gustafsson. (2012) Management of Gastric Carcinoids (Neuroendocrine Neoplasms). Current Gastroenterology Reports 14:6, pages 467-472.
Crossref
Crossref
Andrea Frilling, Goran Åkerström, Massimo Falconi, Marianne Pavel, Jose Ramos, Mark Kidd & Irvin Mark Modlin. (2012) Neuroendocrine tumor disease: an evolving landscape. Endocrine-Related Cancer 19:5, pages R163-R185.
Crossref
Crossref
Matilde Pia Spampatti, Sara Massironi, Roberta Elisa Rossi, Dario Conte, Valentina Sciola, Clorinda Ciafardini, Stefano Ferrero, Lucia Lodi & Maddalena Peracchi. (2012) Unusually aggressive type 1 gastric carcinoid. European Journal of Gastroenterology & Hepatology 24:5, pages 589-593.
Crossref
Crossref
Christina Sæten FjeldboIngunn BakkeSten Even ErlandsenJannicke HolmsethAstrid LægreidArne K. Sandvik, Liv ThommesenTorunn Bruland. (2012) Gastrin upregulates the prosurvival factor secretory clusterin in adenocarcinoma cells and in oxyntic mucosa of hypergastrinemic rats. American Journal of Physiology-Gastrointestinal and Liver Physiology 302:1, pages G21-G33.
Crossref
Crossref
Linda Zhang, Junko Ozao, Richard Warner & Celia Divino. (2011) Review of the Pathogenesis, Diagnosis, and Management of Type I Gastric Carcinoid Tumor. World Journal of Surgery 35:8, pages 1879-1886.
Crossref
Crossref
Chiara Tieppo, Corrado Betterle, Daniela Basso, Claudia Mescoli, Massimo Rugge, Chiara Martini, Valerio Zorzetto, Gemma Maddalo, Nora Cazzagon, Donato Nitti & Fabio Farinati. (2011) Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination. Cancer Immunology, Immunotherapy 60:7, pages 1057-1060.
Crossref
Crossref
Marialuisa Appetecchia & Roberto Baldelli. (2010) Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Journal of Experimental & Clinical Cancer Research 29:1.
Crossref
Crossref
Irvin M. Modlin, Bjorn I. Gustafsson, Steven F. Moss, Marianne Pavel, Apostolos V. Tsolakis & Mark Kidd. (2010) Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease. Annals of Surgical Oncology 17:9, pages 2427-2443.
Crossref
Crossref
Sara Massironi, Dario Conte, Valentina Sciola, Matilde Pia Spampatti, Clorinda Ciafardini, Luca Valenti, Roberta Elisa Rossi & Maddalena Peracchi. (2010) Plasma Chromogranin A Response to Octreotide Test: Prognostic Value for Clinical Outcome in Endocrine Digestive Tumors. American Journal of Gastroenterology 105:9, pages 2072-2078.
Crossref
Crossref
Beom Su Kim, Sung Tae Oh, Jeong Hwan Yook, Kab Choong Kim, Min Gyu Kim, Jun Won Jeong & Byung Sik Kim. (2010) Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses. The American Journal of Surgery 200:3, pages 328-333.
Crossref
Crossref
Mehnaaz Sultan Khuroo, Mohammad Sultan Khuroo & Naira Sultan Khuroo. (2010) Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. Journal of Gastroenterology and Hepatology 25:3, pages 548-554.
Crossref
Crossref
Sara Massironi, Valentina Sciola, Matilde Pia Spampatti, Maddalena Peracchi & Dario Conte. (2009) Gastric carcinoids: Between underestimation and overtreatment. World Journal of Gastroenterology 15:18, pages 2177.
Crossref
Crossref
John Bendelow, Louise Jones & Graeme J. Poston. 2009. Liver Metastases. Liver Metastases
1
8
.
Helge L Waldum, Arne K Sandvik, Eiliv Brenna, Reidar Fossmark, Gunnar Qvigstad & Jun Soga. (2008) Classification of tumours. Journal of Experimental & Clinical Cancer Research 27:1.
Crossref
Crossref
Simona Grozinsky-Glasberg, Ashley B. Grossman & Márta Korbonits. (2008) The role of somatostatin analogues in the treatment of neuroendocrine tumours. Molecular and Cellular Endocrinology 286:1-2, pages 238-250.
Crossref
Crossref
J. Bendelow, E. Apps, L.E. Jones & G.J. Poston. (2008) Carcinoid syndrome. European Journal of Surgical Oncology (EJSO) 34:3, pages 289-296.
Crossref
Crossref
Björn I Gustafsson, Mark Kidd & Irvin M Modlin. (2008) Neuroendocrine tumors of the diffuse neuroendocrine system. Current Opinion in Oncology 20:1, pages 1-12.
Crossref
Crossref
Sylvain Manfredi, Mael Pagenault, Anne-Sophie de Lajarte-Thirouard & Jean-François Bretagne. (2007) Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. European Journal of Gastroenterology & Hepatology 19:11, pages 1021-1025.
Crossref
Crossref
Ursula Plöckinger. (2007) Diagnosis and treatment of gastric neuroendocrine tumoursDiagnose und Therapie gastro-intestinaler neuroendokriner Magentumore. Wiener klinische Wochenschrift 119:19-20, pages 570-572.
Crossref
Crossref
Hank S. Wang, David S. Oh, Gordon V. Ohning & Joseph R. Pisegna. (2007) Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors. Journal of Molecular Neuroscience 33:3, pages 225-231.
Crossref
Crossref
D. Ravizza, G. Fiori, C. Trovato, N. Fazio, G. Bonomo, F. Luca, L. Bodei, G. Pelosi, D. Tamayo & C. Crosta. (2007) Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Digestive and Liver Disease 39:6, pages 537-543.
Crossref
Crossref
Mohammad Fayyaz, Shahid Mehboob, Valerie Andersen & Michael D. Sitrin. (2007) Extended Octreotide Suppression Test to Determine Hormone Responsiveness of Multiple Type I Gastric Carcinoid Tumors. Digestive Diseases and Sciences 52:6, pages 1579-1585.
Crossref
Crossref
Sten Even Erlandsen, Vidar Fykse, Helge L. Waldum & Arne K. Sandvik. (2007) Octreotide induces apoptosis in the oxyntic mucosa. Molecular and Cellular Endocrinology 264:1-2, pages 188-196.
Crossref
Crossref
M. D. BURKITT & D. M. PRITCHARD. (2006) Review article: pathogenesis and management of gastric carcinoid tumours. Alimentary Pharmacology & Therapeutics 24:9, pages 1305-1320.
Crossref
Crossref
Eugene A. Woltering, Ruth S. Hilton, Christy M. Zolfoghary, Jessica Thomson, Stanley Zietz, Vay Liang W. Go, Aaron I. Vinik, Etta Vinik, Thomas M. O'Dorisio & Gregg Mamikunian. (2006) Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid Tumors. Pancreas 33:3, pages 250-254.
Crossref
Crossref
Eva Tiensuu Janson. (2006) Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary 9:3, pages 249-256.
Crossref
Crossref
Gianfranco Delle Fave, Gabriele Capurso, Massimo Milione & Francesco Panzuto. (2005) Endocrine tumours of the stomach. Best Practice & Research Clinical Gastroenterology 19:5, pages 659-673.
Crossref
Crossref